U.S. Markets closed

Wired News – CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018

Stock Monitor: Can-Fite BioPharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on CymaBay Therapeutics, Inc. (NASDAQ: CBAY) ("CymaBay"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBAY as the Company's latest news hit the wire. On April 11, 2018, the Company announced that it will present new data from a second interim analysis of its ongoing Phase-2 study assessing seladelpar in patients with primary biliary cholangitis (PBC) at the International Liver CongressTM hosted by the European Association for the Study of Liver Diseases (EASL) in Paris, France (April 11-15, 2018). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Can-Fite BioPharma Ltd (NYSE AMER: CANF), which also belongs to the Healthcare sector as the Company CymaBay Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CANF

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, CymaBay Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CBAY

Seladelpar Maintains Anti-Cholestatic and Anti-Inflammatory Efficacy Over 26 Weeks of Administration

These data demonstrate that in patients with PBC, seladelpar exhibits potent and sustained anti-cholestatic and anti-inflammatory efficacy over 26 weeks of administration. 71 patients were exposed to at least one dose of seladelpar, of whom 53 received 12 weeks of treatment and 42 received 26 weeks of treatment. At 12 weeks, changes in alkaline phosphatase (AP) were -21%, -33%, and -45% in the 2 mg, 5 mg, and 10 mg groups, respectively. After 12 weeks, dose titration was permitted for patients whose AP remained above normal and at a level where additional AP lowering had the potential to reduce the risk of disease progression. At 26 weeks, decreases in AP were similar across regimens at -45%, -43%, and -43% in the 5 mg, 5 to 10 mg titration and 10 mg groups, respectively. At 26 weeks, 29% of patients had a normal AP. Seladelpar was not associated with drug-induced pruritus. Seladelpar was generally safe and well tolerated, with no transaminase elevation safety signal. There were six serious adverse events, and none were deemed related to seladelpar.

CymaBay to Initiate Phase-3 Study of Seladelpar in H2 2018

Dr. Pol Boudes, M.D., Chief Medical Officer of CymaBay, stated that the Company has now firmly established doses of seladelpar with compelling efficacy and tolerability which is expected to further confirm in a Phase-3 study planned to start in the second half of the year.

Dr. Pol added that these data continue to support the potential for seladelpar to significantly improve treatment options for patients with PBC.

CymaBay to Present New Data Demonstrating Seladelpar's Pharmacokinetic and Pharmacodynamic Profile

The Company will also present new data highlighting the mechanism of action of seladelpar and its pharmacokinetic and pharmacodynamic profile at The International Liver CongressTM. Seladelpar demonstrates multiple beneficial activities that address the underlying pathophysiology of PBC and NASH. The pharmacokinetics of seladelpar in PBC patients supports a once daily dosing regimen, appears to be dose proportional and the level of exposure correlates with its pharmacodynamic activities.

About Primary Biliary Cholangitis

PBC, also known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. Further slow damage to the liver tissue can lead to scarring, fibrosis, and eventually cirrhosis. Common symptoms are tiredness, itching and, in more advanced cases, jaundice. In early cases, there may only be changes in blood tests.

CymaBay Began Enrollment in Long-term Extension Study of Seladelpar in PBC Patients

On January 08, 2018, the Company announced that the first PBC patients were successfully enrolled in the seladelpar long-term extension study (NCT03301506). The extension study is an international Phase-2/3 study that will provide access to long-term seladelpar treatment for patients enrolled in a previous or ongoing study evaluating seladelpar for the treatment of PBC. The objectives of the study are to provide additional long-term safety and efficacy data that will support the seladelpar registration program and to follow patients until registration of seladelpar.

About Seladelpar

Seladelpar (MBX-8025) is an orally administered, potent, and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and non-alcoholic steatohepatitis (NASH). Seladelpar is uniquely suited as a treatment for liver disease. Preclinical and clinical data support its effect on bile acids synthesis, inflammation, fibrosis, and cellular metabolism.

About CymaBay Therapeutics, Inc.

Headquartered in Newark, California, CymaBay is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area. The Company is focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases.

Stock Performance Snapshot

April 12, 2018 - At Thursday's closing bell, CymaBay Therapeutics' stock dropped 2.60%, ending the trading session at $13.09.

Volume traded for the day: 2.38 million shares, which was above the 3-month average volume of 1.26 million shares.

Stock performance in the last three-month – up 35.93%; previous six-month period – up 46.42%; past twelve-month period – up 210.93%; and year-to-date - up 42.28%

After yesterday's close, CymaBay Therapeutics' market cap was at $736.18 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.8% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors